Novavax Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
20,915.00
30,659.00
36,250.00
15,353.00
31,176.00
Cost of Goods Sold (COGS) incl. D&A
8,222.00
14,987.00
-
-
-
Gross Income
12,693.00
15,672.00
-
-
-
SG&A Expense
63,827.00
99,363.00
193,486.00
275,961.00
193,069.00
EBIT
51,134.00
83,691.00
163,219.00
269,113.00
171,710.00
Unusual Expense
1,033.00
-
-
-
-
Non Operating Income/Expense
182.00
615.00
120.00
31.00
67.00
Interest Expense
160.00
157.00
241.00
12,965.00
14,072.00
Pretax Income
51,958.00
82,947.00
156,937.00
279,966.00
183,769.00
Consolidated Net Income
51,983.00
82,947.00
156,937.00
279,966.00
183,769.00
Net Income
51,983.00
82,947.00
156,937.00
279,966.00
183,769.00
Net Income After Extraordinaries
51,983.00
82,947.00
156,937.00
279,966.00
183,769.00
Net Income Available to Common
51,983.00
82,947.00
156,937.00
279,966.00
183,769.00
EPS (Basic)
0.31
0.37
0.60
1.03
0.63
Basic Shares Outstanding
169,658.00
225,848.00
262,248.00
270,802.00
292,669.00
EPS (Diluted)
0.31
0.37
0.60
1.03
0.63
Diluted Shares Outstanding
169,658.00
225,848.00
262,248.00
270,802.00
292,669.00
EBITDA
48,543.00
79,267.00
157,236.00
260,608.00
161,893.00
Non-Operating Interest Income
187.00
286.00
660.00
2,143.00
1,946.00
About Novavax
View Profile
